Bae Jihong, Park Joo-Hwan, Kim Young Saing, Ahn Hee Kyung, Cho Eun Kyung, Shin Dong Bok, Park Ji-Hyeon, Yang Jun-Young, Lee Woon Kee, Sym Sun Jin
Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Department of Surgery, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Cancer Med. 2025 Aug;14(15):e71079. doi: 10.1002/cam4.71079.
TS-1 at 80 mg/m/day for 4 weeks followed by a 2-week rest is standard adjuvant therapy for stage II/III Advanced Gastric Cancer (AGC). TS-1 for 1 year (8 courses) is highly recommended. We investigated the efficacy and safety of an adjuvant 3-weekly TS-1 regimen for AGC.
We analyzed 93 patients with stage II/III AGC who started 3-weekly adjuvant TS-1 therapy between Feb 2017 and May 2022 post-gastrectomy with D2 lymphadenectomy. The 3-weekly regimen was TS-1 at 80 mg/m/day for 2 weeks, followed by a 1-week rest for 1 year (16 courses).
Among 93 patients, 12 (13%) had disease recurrence during follow-up (median 24.6 months, range 4.2%-63.3%). Seven (9.5%) with stage II (n = 73) and five (25%) with stage III (n = 20) experienced recurrence. Kaplan-Meier analysis estimated that Recurrence-Free Survival (RFS) rates at 1, 3, and 5 years were 92.0% (95% CI; 86.5%-97.9%), 84.7% (95% CI; 76.4%-93.9%), and 78.6% (95% CI; 65.8%-94.0%), respectively. Eighty patients (86%) completed the treatment; 25 (26.9%) needed dose reduction. Adverse events, mostly grade 1 or 2 diarrhea (28%) and nausea (20%), were manageable.
Our study revealed that the 3-weekly TS-1 regimen as adjuvant therapy exhibited good efficacy and manageable toxicity. This regimen as an adjuvant therapy for AGC should be evaluated in future studies.
对于II/III期进展期胃癌（AGC），标准辅助治疗方案是给予替吉奥（TS-1）80mg/m²/天，持续4周，随后休息2周。强烈推荐使用替吉奥治疗1年（8个疗程）。我们研究了AGC辅助治疗中每3周一次替吉奥方案的疗效和安全性。
我们分析了93例II/III期AGC患者，这些患者在2017年2月至2022年5月间接受了D2淋巴结清扫胃切除术后开始每3周一次的辅助替吉奥治疗。每3周一次的方案是给予替吉奥80mg/m²/天，持续2周，随后休息1周，共治疗1年（16个疗程）。
93例患者中，12例（13%）在随访期间出现疾病复发（中位时间24.6个月，范围4.2%-63.3%）。II期患者（n = 73）中有7例（9.5%）复发，III期患者（n = 20）中有5例（25%）复发。Kaplan-Meier分析估计，1年、3年和5年的无复发生存率（RFS）分别为92.0%（95%CI：86.5%-97.9%）、84.7%（95%CI：76.4%-93.9%）和78.6%（95%CI：65.8%-94.0%）。80例患者（86%）完成了治疗；25例（26.9%）需要减量。不良事件大多为1级或2级腹泻（28%）和恶心（20%），可控制。
我们的研究表明，每3周一次的替吉奥方案作为辅助治疗显示出良好的疗效且毒性可控。该方案作为AGC的辅助治疗应在未来研究中进行评估。
